Compare SWKH & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | CVRX |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Diversified Financial Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 221.2M |
| IPO Year | 1999 | 2021 |
| Metric | SWKH | CVRX |
|---|---|---|
| Price | $17.16 | $7.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $18.00 | $13.17 |
| AVG Volume (30 Days) | 10.3K | ★ 159.4K |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | $40,149,000.00 | ★ $55,969,000.00 |
| Revenue This Year | $52.93 | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | $9.19 | ★ N/A |
| Revenue Growth | ★ 62.38 | 18.44 |
| 52 Week Low | $13.17 | $4.30 |
| 52 Week High | $20.49 | $18.55 |
| Indicator | SWKH | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 31.55 |
| Support Level | $17.00 | $7.14 |
| Resistance Level | $17.45 | $8.44 |
| Average True Range (ATR) | 0.28 | 0.54 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 58.94 | 22.59 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.